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In 1633, after many years of skirmishing with the
Catholic Church over his support for Copernicus’
heliocentric theory of the universe, Galileo was finally
sentenced by the inquisition to prison and religious
penances. In a formal ceremony at the church of
Santa Maria Sofia Minerva, he was forced to abjure
his errors, and spent the rest of his life under house
arrest in Sienna. The prophet had been convicted as
a heretic.
Without, yet, wishing to confer the status of prophet
on Peter Aaby and his disciples based in Guinea
Bissau, there are significant parallels in their persistent
challenges to some of the deepest rooted public health
orthodoxies of the present day. Aaby has a long history
of interrogating datasets in a way that others have
failed to do and coming up with some uncomfortable
findings. For many years he has been in conflict
with WHO and many vaccinologists concerning his
beliefs that childhood vaccines can have non-specific
downstream effects on mortality (sometimes positive,
but often negative) that have been ignored by main-
stream research.
1–4 More recently his team have even
challenged, on the basis of a randomized trial, the
value of WHO’s recommendation that exclusive
breastfeeding should continue to 6 months.
5 Some
may consider that house arrest is too lenient, even in
Guinea Bissau instead of Sienna.
Christine Stabell Benn, working within Aaby’s
group, has for several years been pursuing another
line of heresy, namely that it may be beneficial
to withhold vitamin A supplementation (VAS) from
infant girls in developing countries, at least until they
have had their first measles vaccination.
6–8 In this
issue of IJE,
9 the Bissau team summarize the evidence
in support of their belief that co-administration of
vitamin A with diphtheria–tetanus–pertussis vaccine
(DTP) results in negative interactions that lead to
higher subsequent mortality; an effect confined to
girls. They then take this a step further by drawing
on data from two very large trials of zinc and iron-
plus-folic-acid supplementation from Nepal
10,11 and
Zanzibar (Pemba).
12,13 Using these data they argue
that these trials also reveal important sex and age-
differential effects of preventive treatment with micro-
nutrients with a ‘tendency’ for detrimental effects
in infants especially among girls.
9 They conclude that
micronutrient supplementation policies might have
to differ for boys and girls, and that in their view
‘all evidence suggests that currently infant girls have
little to gain from micronutrients’.
9
Could it really be true that in populations such as
rural West Africa (where anaemia rates can exceed
90% and where 470% of young children can have
plasma retinol levels <0.7mmol/l
14), we can advocate
that micronutrients should be withheld from girls?
Is it really possible that marginal nutrient deficiencies
might be protective where infections are highly
prevalent, as recently postulated for iron?
15 Only
a few years ago such a view, which is in direct con-
flict with policy recommendations from WHO,
16,17
the International Vitamin A Consultative Group
(IVACG)
18 and the International Nutritional
Anemias Consultative Group (INACG),
19 would have
been condemned as heresy. However, the recent
findings from the Pemba trial
12 that supplementation
with iron-plus-folic-acid caused a significant increase
in serious adverse events and mortality leading
to the trial’s termination by its Data and Safety
Monitoring Board have brought a renewed humility,
and a recognition that there can be complex inter-
actions between micronutrients, pathogens and
immunity.
20 The state of our collective ignorance
has been made painfully apparent.
21
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doi:10.1093/ije/dyn363The evidence garnered by Benn and colleagues in
support of their central contention that there are
negative interactions between VAS and DTP vaccina-
tion in girls is somewhat fragmentary and often based
on non-significant trends. Some of it is vulnerable to
possible ascertainment biases related both to records
of deaths and of vaccination status; criticisms of
which the Guinea Bissau group are well aware,
22,23
and which they endeavour to incorporate into their
analyses. The evidence is complex and has been
recently considered by a group of experts (including
Benn and Aaby) convened at the London School of
Hygiene & Tropical Medicine (LSHTM). It would be
presumptive of us to offer a definite adjudication
on the Benn thesis, or to pre-empt any report that
may emerge from the LSHTM group. However, we
offer the following recommendations:
(i) There is sufficient circumstantial evidence for
the Benn/Aaby thesis to be taken seriously; as
has recently occurred at the LSHTM meeting.
Those public health nutritionists or vaccino-
logists who tend towards the evangelical would
be wise to leave room for scepticism and open
debate.
(ii) One of the major aims of the London meeting
was to gather together additional existing
datasets that may be able to contribute further
evidence for or against the Benn/Aaby hypoth-
esis. Such datasets need to be very large
given the welcome fact that infant and child
mortality rates are declining in most countries
and we may be searching for relatively rare
endpoints and modest effect sizes. Impartial
third-party re-analysis of such datasets should
be expedited and, in view of the latest sug-
gestion that the negative interactions may
extend to supplementation with zinc and
iron-plus-folic-acid, it is hoped that the Johns’
Hopkins group have already been asked to
contribute the data from their Nepal and
Zanzibar trials
10–13 so that the appropriate
re-analysis can be done.
(iii) It would be unethical to conduct a prospective
4-arm trial in which infants were randomized
with and without vitamin A and with and
without DTP, but it might still be ethically
acceptable to conduct a trial in which the
vitamin A treatment was randomized (depend-
ing on the ethics committee’s level of convic-
tion concerning the Benn/Aaby hypothesis).
However, much of the evidence accrued so far
has come from areas with very high mortality
and any research team initiating a new trial
would have a moral responsibility to put in
place better health surveillance and care,
which, by reducing the number of serious
adverse events, would probably require any
such trial to be so large as to be prohibitively
costly irrespective of any ethical arguments.
Therefore the prospects of obtaining RCT
standard evidence are remote.
(iv) Aaby’s contention that vaccines can have
potent and long-lasting unintended effects
has important implications for the design and
analysis of vaccine trials. Since post-marketing
(Phase 4) data surveillance is not currently
practicable in most developing country settings,
there is a responsibility to try and assess such
outcomes at the Phase 3 stage with long-term
follow-up and assessment of multiple outcomes,
not just those related to the target disease.
(v) There is an urgent need to introduce a greater
sophistication and more modern immunological
techniques in order to understand the com-
plex interactions between micronutrients and
vaccines. Although community-wide VAS has
been repeatedly proven to reduce all cause
mortality in children, we know virtually noth-
ing about the mechanism by which it saves
lives.
21,24 It is striking that Benn and colleagues
are able to muster very little in the way of
supportive mechanistic theories as to why there
may be negative interactions and why these
might be sex-specific. Even if large trials with
mortality outcomes are not possible, it should
be feasible to learn more about the putative
interactions by means of very detailed investi-
gations into how DTP and vitamin A status
interact to modulate the downstream effects of
the vaccine (for instance in relation to sugges-
tions that it may exaggerate sex-specific
T-helper cell biases).
(vi) Contrary to the frequently cited statement that
‘it would be unethical’ to perform trials in
which vitamin A (or iron) were withheld in a
control group, we believe that recent findings
have re-established an ethical equipoise and
that it is now essential to conduct such trials.
(vii) In the light of the concerns about vitamin A
and DTP, and in view of the fact that at least
two studies have shown that high doses of
vitamin A can be associated with poorer clinical
outcomes,
8,25 and that measles vaccination
appears to cancel out any adverse consequences
of VASþDTP,
9,26 it may be wise to modify the
current WHO advice concerning the timing of
first VAS in infants. Currently the recommen-
dation is ‘after 6 months’.
17 A prudent
approach might to be recommend ‘with, or
soon after, measles vaccination’.
(viii) Public health nutritionists have generally
moved on from single micronutrient interven-
tions (vitamin A, iron, zinc and iodine) and
are busily exploring the efficacy of multiple
micronutrients in the form of Sprinkles or
lipid-based nutrient supplements (LNS). The
inclusion of long-chain polyunsaturated fatty
acids, which are already known to have
592 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYpotentially significant immunomodulatory pro-
perties,
27 is being considered in LNS for-
mulation. What effects might these other
micronutrients have on vaccine responses?
These should also be studied using, in the
first instance, careful assays of their proximal
effects on immune function.
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